Revance Therapeutics reported $29.01M in Sales Revenues for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Abbvie ABBV:US USD 14.81B 229M
ALKERMES ALKS:US USD 252.36M 23.86M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Cara Therapeutics CARA:US USD 10.81M 12.19M
Coherus Biosciences CHRS:US USD 45.42M 14.73M
Eli Lilly And LLY:US USD 7.3B 360.2M
Endo International Ordinary Shares ENDP:US USD 541.69M 27.42M
Horizon Pharma HZNP:US USD 925.36M 48.95M
JAZZ PHA JAZZ:US USD 940.65M 7.77M
Johnson & Johnson JNJ:US USD 23.71B 85M
Merk MRK:US USD 13.83B 1.13B
Neurocrine Biosciences NBIX:US USD 387.9M 9.7M
Pacira Pharmaceuticals PCRX:US USD 167.47M 1.94M
Procter & Gamble PG:US USD 20.77B 161M
Revance Therapeutics RVNC:US USD 29.01M 647K
Supernus Pharmaceuticals SUPN:US USD 177.35M 7.3M
Teva Pharmaceutical Industries TEVA:US USD 3.6B 191M